Eisai Co. (ESAIY) and Biogen (BIIB) announced that humanized anti- soluble aggregated amyloid-beta monoclonal antibody “LEQEMBI” has been approved in China as a treatment of mild cognitive impairment due to Alzheimer’s disease and mild AD dementia. Preparations for launch within the second quarter of Eisai’s FY 2024, July 1 – September 30, 2024, are underway, the companies stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BIIB: